The application advances of bisphosphonates in bone metastasis.
- Author:
Peng LIANG
1
Author Information
1. Department of Orthopaedics, the Gansu Cancer Hospital, Lanzhou 730050, Gansu, China. liangplz0801@hotmail.com
- Publication Type:Journal Article
- MeSH:
Apoptosis;
drug effects;
Bone Neoplasms;
drug therapy;
pathology;
secondary;
Diphosphonates;
adverse effects;
pharmacology;
therapeutic use;
Humans;
Neoplasm Invasiveness
- From:
China Journal of Orthopaedics and Traumatology
2008;21(6):480-482
- CountryChina
- Language:Chinese
-
Abstract:
Bone metastases is a serious complication of patients with tumor. It is associated with substantial morbidity, including bone pain, pathological fracture,neurological deficit and (or) hypercalcemia. Thus, the management of bone metastasis is a clinically significant issue. Bisphosphonates have now become a part of standard therapy to treat and prevent skeletal-related events (SRE), it could inhibit osteoclast-mediated bone resorption and demonstrate antitumor activity in preclinical models. Bisphosphonates are the most effective agent for treating and (or) preventing complications of bone metastasis, reducing the incidence of skeletal-related events, and improving quality of life in patients with bone metastasis.
